← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

Sight Sciences, Inc. (SGHT) 10-Year Financial Performance & Capital Metrics

SGHT • • Industrial / General
HealthcareMedical DevicesSurgical & Minimally Invasive DevicesOphthalmic Surgical Devices
AboutSight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.Show more
  • Revenue $80M -1.5%
  • EBITDA -$50M +12.1%
  • Net Income -$52M +7.3%
  • EPS (Diluted) -1.03 +9.6%
  • Gross Margin 85.5% +0.2%
  • EBITDA Margin -62.38% +10.8%
  • Operating Margin -63.27% +10.5%
  • Net Margin -64.49% +5.9%
  • ROE -49.59% -25.1%
  • ROIC -302.85% +2.9%
  • Debt/Equity 0.46 +56.5%
  • Interest Coverage -10.84 -2.3%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 93 (top 7%)
  • ✓Strong 5Y sales CAGR of 27.9%

✗Weaknesses

  • ✗Weak Piotroski F-Score: 3/9
  • ✗Negative free cash flow
  • ✗Low quality earnings: Net income not backed by cash flow

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y27.89%
3Y17.72%
TTM-4.39%

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM8.42%

EPS CAGR

10Y-
5Y-
3Y-
TTM11.76%

ROCE

10Y Avg-93.34%
5Y Avg-42.05%
3Y Avg-34.99%
Latest-35.87%

Peer Comparison

Ophthalmic Surgical Devices
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
SGHTSight Sciences, Inc.348.95M6.60-6.41-1.47%-60.63%-71.72%0.46
RXSTRxSight, Inc.402.53M9.79-13.7957.09%-25.15%-12.95%0.04

Profit & Loss

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+7.53M23.35M27.64M48.96M71.33M81.06M79.87M
Revenue Growth %-2.1%0.18%0.77%0.46%0.14%-0.01%
Cost of Goods Sold+2.34M6.54M9.21M8.61M12.36M11.88M11.58M
COGS % of Revenue0.31%0.28%0.33%0.18%0.17%0.15%0.15%
Gross Profit+5.19M16.8M18.43M40.35M58.97M69.17M68.28M
Gross Margin %0.69%0.72%0.67%0.82%0.83%0.85%0.85%
Gross Profit Growth %-2.24%0.1%1.19%0.46%0.17%-0.01%
Operating Expenses+19.49M40.84M50.62M91.82M142.92M126.45M118.82M
OpEx % of Revenue2.59%1.75%1.83%1.88%2%1.56%1.49%
Selling, General & Admin14.06M32.72M41.74M76.19M120.06M108.89M100.83M
SG&A % of Revenue1.87%1.4%1.51%1.56%1.68%1.34%1.26%
Research & Development5.43M8.12M8.87M15.63M22.86M17.56M17.99M
R&D % of Revenue0.72%0.35%0.32%0.32%0.32%0.22%0.23%
Other Operating Expenses0000000
Operating Income+-14.3M-24.04M-32.19M-51.48M-83.95M-57.27M-50.53M
Operating Margin %-1.9%-1.03%-1.16%-1.05%-1.18%-0.71%-0.63%
Operating Income Growth %--0.68%-0.34%-0.6%-0.63%0.32%0.12%
EBITDA+-14.23M-23.61M-31.63M-50.28M-82.7M-56.66M-49.82M
EBITDA Margin %-1.89%-1.01%-1.14%-1.03%-1.16%-0.7%-0.62%
EBITDA Growth %--0.66%-0.34%-0.59%-0.64%0.31%0.12%
D&A (Non-Cash Add-back)63K432K554K1.2M1.25M614K712K
EBIT-14.3M-23.9M-32.23M-58.41M-81.73M-50.03M-46.61M
Net Interest Income+1K-1.79M-2.37M-4.37M-4.47M-5.41M-4.66M
Interest Income1K174K30K0000
Interest Expense01.96M2.4M4.37M4.47M5.41M4.66M
Other Income/Expense1K-1.82M-2.44M-11.29M-2.24M1.84M-739K
Pretax Income+-14.3M-25.86M-34.63M-62.77M-86.19M-55.44M-51.27M
Pretax Margin %-1.9%-1.11%-1.25%-1.28%-1.21%-0.68%-0.64%
Income Tax+-6K8K61K188K47K110K236K
Effective Tax Rate %1%1%1%1%1%1%1%
Net Income+-14.29M-25.87M-34.69M-62.96M-86.24M-55.55M-51.51M
Net Margin %-1.9%-1.11%-1.26%-1.29%-1.21%-0.69%-0.64%
Net Income Growth %--0.81%-0.34%-0.81%-0.37%0.36%0.07%
Net Income (Continuing)-14.29M-25.87M-34.69M-62.96M-86.24M-55.55M-51.51M
Discontinued Operations0000000
Minority Interest0000000
EPS (Diluted)+-0.44-0.77-0.74-1.33-1.80-1.14-1.03
EPS Growth %--0.75%0.04%-0.8%-0.35%0.37%0.1%
EPS (Basic)-0.44-0.55-0.74-1.33-1.80-1.14-1.03
Diluted Shares Outstanding32.2M33.63M46.77M47.5M47.85M48.63M50.13M
Basic Shares Outstanding32.2M33.63M46.77M47.5M47.85M48.63M50.13M
Dividend Payout Ratio-------

Balance Sheet

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+7.16M28M70.63M277.04M209.68M162.87M139.77M
Cash & Short-Term Investments4.24M21.24M61.51M260.69M185M138.13M120.36M
Cash Only4.24M21.24M61.51M260.69M185M138.13M120.36M
Short-Term Investments0000000
Accounts Receivable1.81M4.09M5.36M8.71M15.15M14.29M10.79M
Days Sales Outstanding87.986470.8264.9377.5164.3449.29
Inventory486K2.24M2.6M3.48M6.11M7.85M6.33M
Days Inventory Outstanding75.87125.16102.97147.31180.54241.13199.35
Other Current Assets00003.42M2.6M2.31M
Total Non-Current Assets+930K2.74M2.17M3.15M3.4M3.78M3.06M
Property, Plant & Equipment868K2.57M1.79M2.95M3.19M3.1M2.52M
Fixed Asset Turnover8.68x9.08x15.47x16.60x22.40x26.16x31.76x
Goodwill0000000
Intangible Assets0000000
Long-Term Investments0000000
Other Non-Current Assets62K168K386K202K211K682K550K
Total Assets+8.09M30.74M72.81M280.19M213.07M166.65M142.84M
Asset Turnover0.93x0.76x0.38x0.17x0.33x0.49x0.56x
Asset Growth %-2.8%1.37%2.85%-0.24%-0.22%-0.14%
Total Current Liabilities+2.9M7.34M9.31M13.5M17.82M12.25M15.47M
Accounts Payable1.88M2.31M2.16M3.35M2.69M1.73M1.69M
Days Payables Outstanding293.34129.1285.53142.0679.3753.1853.3
Short-Term Debt000002.22M0
Deferred Revenue (Current)0000000
Other Current Liabilities328K04.07M5.99M7.35M4.53M9.68M
Current Ratio2.47x3.82x7.58x20.52x11.77x13.29x9.04x
Quick Ratio2.31x3.51x7.30x20.26x11.43x12.65x8.63x
Cash Conversion Cycle-129.4960.0488.2670.19178.68252.3195.34
Total Non-Current Liabilities+34.16M78.09M152.34M34.58M35.18M34.18M39.85M
Long-Term Debt34.15M12.86M31.95M32.66M33.31M31.71M39.36M
Capital Lease Obligations0528K134K1.04M635K914K473K
Deferred Tax Liabilities0000000
Other Non-Current Liabilities7K64.7M120.25M879K1.23M1.56M19K
Total Liabilities37.06M85.42M161.66M48.08M53M46.44M55.32M
Total Debt+34.15M13.94M32.48M34.21M34.98M35.41M40.36M
Net Debt29.91M-7.3M-29.03M-226.48M-150.02M-102.72M-80M
Debt / Equity---0.15x0.22x0.29x0.46x
Debt / EBITDA-------
Net Debt / EBITDA-------
Interest Coverage--12.26x-13.39x-11.79x-18.80x-10.59x-10.84x
Total Equity+-28.96M-54.68M-88.85M232.11M160.08M120.22M87.52M
Equity Growth %--0.89%-0.62%3.61%-0.31%-0.25%-0.27%
Book Value per Share-0.90-1.63-1.904.893.352.471.75
Total Shareholders' Equity-28.96M-54.68M-88.85M232.11M160.08M120.22M87.52M
Common Stock9K9K9K48K48K49K51K
Retained Earnings-29.48M-55.35M-90.04M-153M-239.24M-294.79M-346.3M
Treasury Stock0000000
Accumulated OCI-34.15M-64.49M00000
Minority Interest0000000

Cash Flow

Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-14.47M-25M-32.17M-52.54M-75.97M-47.18M-22.35M
Operating CF Margin %-1.92%-1.07%-1.16%-1.07%-1.06%-0.58%-0.28%
Operating CF Growth %--0.73%-0.29%-0.63%-0.45%0.38%0.53%
Net Income-14.29M-25.87M-34.69M-62.96M-86.24M-55.55M-51.51M
Depreciation & Amortization63K295K554K632K710K614K712K
Stock-Based Compensation52K118K497K5.08M12.96M14.58M17.08M
Deferred Taxes0007.76M000
Other Non-Cash Items58K800K684K1.27M2.3M2.3M2.37M
Working Capital Changes-358K-341K784K-4.33M-5.7M-9.13M9M
Change in Receivables-1.42M-2.32M-1.48M-3.69M-6.84M661K3.54M
Change in Inventory-184K-1.8M-1.72M-1.31M-3.25M-2.16M1.63M
Change in Payables1M168K448K1.17M-694K-883K336K
Cash from Investing+-570K-672K-953K-813K-970K-791K-385K
Capital Expenditures-570K-672K-953K-813K-970K-791K-385K
CapEx % of Revenue0.08%0.03%0.03%0.02%0.01%0.01%0%
Acquisitions-------
Investments-------
Other Investing0000000
Cash from Financing+12.2M42.66M73.4M252.53M1.25M1.1M4.96M
Debt Issued (Net)-------
Equity Issued (Net)-------
Dividends Paid0000000
Share Repurchases-------
Other Financing-23K-2.09M-154K-4.15M0-224K-261K
Net Change in Cash-------
Free Cash Flow+-15.04M-25.67M-33.13M-53.35M-76.94M-47.98M-22.74M
FCF Margin %-2%-1.1%-1.2%-1.09%-1.08%-0.59%-0.28%
FCF Growth %--0.71%-0.29%-0.61%-0.44%0.38%0.53%
FCF per Share-0.47-0.76-0.71-1.12-1.61-0.99-0.45
FCF Conversion (FCF/Net Income)1.01x0.97x0.93x0.83x0.88x0.85x0.43x
Interest Paid01.15M1.29M0000
Taxes Paid0000000

Key Ratios

Metric2018201920202021202220232024
Return on Equity (ROE)----87.9%-43.98%-39.64%-49.59%
Return on Invested Capital (ROIC)-1129.9%---686.25%-802.98%-311.76%-302.85%
Gross Margin68.95%71.97%66.68%82.41%82.67%85.34%85.5%
Net Margin-189.77%-110.8%-125.52%-128.61%-120.9%-68.53%-64.49%
Debt / Equity---0.15x0.22x0.29x0.46x
Interest Coverage--12.26x-13.39x-11.79x-18.80x-10.59x-10.84x
FCF Conversion1.01x0.97x0.93x0.83x0.88x0.85x0.43x
Revenue Growth-210.07%18.38%77.12%45.7%13.63%-1.47%

Revenue by Segment

2021202220232024
Surgical Glaucoma46.5M65.59M74.31M75.9M
Surgical Glaucoma Growth-41.07%13.29%2.14%
Dry Eye2.46M5.74M6.75M3.96M
Dry Eye Growth-133.21%17.59%-41.24%

Frequently Asked Questions

Growth & Financials

Sight Sciences, Inc. (SGHT) reported $76.1M in revenue for fiscal year 2024. This represents a 910% increase from $7.5M in 2018.

Sight Sciences, Inc. (SGHT) saw revenue decline by 1.5% over the past year.

Sight Sciences, Inc. (SGHT) reported a net loss of $46.1M for fiscal year 2024.

Dividend & Returns

Sight Sciences, Inc. (SGHT) has a return on equity (ROE) of -49.6%. Negative ROE indicates the company is unprofitable.

Sight Sciences, Inc. (SGHT) had negative free cash flow of $31.8M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.